Fall of the Titans  by Canavero, Sergio & Bonicalzi, Vincenzo
409www.engineering.org.cn  Volume 1 · Issue 4 · December 2015  Engineering
Views & Comments
Engineering 2015, 1(4): 409–412
DOI  10.15302/J-ENG-2015092Fall of the Titans 
The Demise of Basic Neuroscience Research
By Sergio Canavero* and Vincenzo Bonicalzi
 Turin Advanced Neuromodulation Group, Turin 10132, Italy
* Correspondence author. E-mail: sercan@inwind.it
© The Author(s) 2015. Published by Engineering Sciences Press. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
The preface to the 2011 edition of Goodman and Gilman’s the 
Pharmacological Basis of Therapeutics (12th ed) penned by top 
pharmacologist professor Laurence L. Brunton, the chief edi-
tor, reads: 
The process of editing brings into view many remarkable facts, 
theories, and realizations. Three stand out: the invention of new 
classes of drugs has slowed to a trickle; therapeutics has barely 
begun to capitalize on the information from the human genome 
project; and, the development of resistance to antimicrobial 
agents, mainly through their overuse in medicine and agricul-
ture, threatens to return us to the pre-antibiotic era. 
On the other hand, an editorial in Lancet claims that 
The basic medical sciences are not only being neglected, they 
are being systematically eroded. This marginalisation will have 
damaging effects on clinical care over the next two decades…Pa-
tient care will be harmed… [1]
In fact, such repositories as PubMed and Embase liter-
ally include tens of millions of scientific papers, a majority 
devoted to basic clinical research. In light of Brunton’s asser-
tions, something must be wrong, or major progress against 
neurodegenerative and other conditions, would surely have 
ensued. The two “top-dog” journals in the business of basic 
research, including medicine, are Nature and Science. Biomed-
ical research published in these two weeklies is often given 
spectacular media coverage, and one is led to believe that 
such articles truly advance the state of the art in medicine. 
Moreover, these publications are the ground for much phar-
maceutical experimentation, as well as academic promotion.
1 The inconvenient truth
For our part, the first hints of something being awfully 
wrong came from articles published in Nature concerning the 
“discovery” of a pain-speciﬁ c nucleus in the human thalamus 
in 1994 which was later found to be non-existent (“a myth” [2]). 
The second clue came from the widely publicized media case 
of a minimally conscious patient who improved with deep 
brain stimulation in 2007, a feat that had already been re-
ported by others years before (see Ref. [3]). Last but not least, 
no single paper published in Nature or Science over the past 30 
years or so resulted in an effective treatment of neuropathic 
pain, one of our primary research focuses (unpublished ob-
servations). As has been highlighted, many Nobel Prize win-
ners have had their work rejected by Nature and/or by Science 
(e.g., Fermi, Cherenkov, Krebs, Yukawa, and more) and the 
inventor of the polymerase chain reaction, Gary Mullis, was 
rejected by both [4], so this lack of progress should have not 
been totally unexpected.
We therefore set out to assess the therapeutic relevance 
of articles published in these two journals to clinical neurol-
ogy. Neurology is one of the two specialties most represented 
among papers of biomedical relevance in both journals (Table 1, 
Figure 1, and Table 2). Our ﬁ nal aim was to ascertain if a drug 
(or procedure) stemming from such studies had reached the 
US Food and Drug Administration (FDA) or European Agen-
cy for the Evaluation of Medicinal Products (EMEA) approval 
and if the proposed therapeutic intervention had made it into 
standard clinical care, as assessed in contemporary, updated 
textbooks and databases. Diagnostic contributions were not 
considered, since arguably diagnosis without therapy is quite 
sterile to both the patient and the doctor. In addition, we did 
not consider papers dealing with the supposed elucidation of 
pharmacological mechanisms of action, unless the authors 
made therapeutically relevant observations. We assessed pri-
mary research only (Science: research articles, reports; Nature: 
articles, letters, and brief communications), but not reviews 
or progress articles. Only papers whose conclusions clearly 
highlighted the therapeutic relevance of the results and 
with clear-cut claims were included (see the Supplementary 
Information, Tables S1 to S4).
Table 1. Break-down of research papers according to experimental model.
Experimental
model
Science 1990
75 papers
Science 2000
66 papers
Nature 1990
40 papers
Nature 2000
69 papers
Rodents 22 (29%) 27 (41%) 17 (42%) 32 (46%)
Biochemistry 12 (16%) 19 (29%) 10 (25%) 14 (20%)
Cell culture 29 (39%) 7 (11%) 11 (27%) 12 (17%)
Bacterial culture 0 0 1 2
Monkeys 3 4 1 2
Drosophila 0 3 0 2
Humans 7 3 0 5
Other 2 3 0 0
Given the supposedly high standards of refereeing applied 
by these two journals and their Impact Factor-supported ca-
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chet, we set stringent standards of assessment. A paper would 
pass muster only if:
(1) The authors clearly stated or implied that the molecule 
or procedure under study would substantially advance 
the treatment of a clinical condition;
(2) No previous or contemporary paper on the target study 
leading to similar conclusions was identiﬁ ed, that is, the 
conclusions were completely original (new) and thus ﬁ t 
for a potential patent application; and
(3) Without that paper, the treatment as per above would 
not have been possible.
We initially selected the year 2000 and assessed the predic-
tions as of December 31, 2014. The process of drug develop-
ment takes eight and a half years and includes: preclinical tri-
als, involving animal and other laboratory tests (lasting one 
and a half years on average); clinical trials, involving tests on 
humans (five years); and FDA review (two years) [5]. Good-
man and Gilman’s the Pharmacological Basis of Therapeutics (2006, 
p. 134) provides similar figures (global average 9.2 years, 
range 4–16 years). Consequently, a span of 14 years seemed 
adequate for the initial assessment. In fact, one might expect 
that the pharmaceutical and device industry would constant-
ly monitor such research and then pursue the results in an 
expeditious fashion. Thirty-seven papers were culled from 
the two. Each article was assessed individually. Not a single 
piece of research published in these two prestigious journals 
led per se to a ground-breaking, clinically effective molecule 
or procedure, even though major innovations would have 
been expected—for example, for Alzheimer’s and Parkinson’s 
diseases. Many groups touted their ﬁ ndings as a real break-
through, in general arising from “simple” interference with 
a single molecule or biochemical pathway. In fact, several pa-
pers appear to be a strange smorgasbord of animal, genetic, 
and biochemical data, and it is not even clear upon which 
data the authors based their overblown conclusions. Neurol-
ogy has not beneﬁ ted from Drosophila’s experiments, either.
It may be argued that the 14 year cut-off is still too short a 
time for a fair assessment of research [6]. We thus repeated 
the same kind of analysis for the year 1990. It is reasonable to 
suppose that if a study has not led to tangible advances in the 
clinic after more than two decades, most likely it was either 
irrelevant or later rejected by further research. Nineteen pa-
pers were culled from the two journals. Results are similar to 
the previous analysis. A few examples include:
(1) Apparently, Bergman et al.’s study (Science, Sep. 21) 
paved the way to subthalamic (STN) surgery for Par-
kinson’s disease. On closer scrutiny, however, the merit 
goes to the Oxford Movement Disorder Group. In a 
paper published in 1991 (Aziz et al., Movement Disord., 
Figure 1. Break-down of research paper according to specialty and journal. Infect dis: infectious disease. Neurol: neurology. Cardiol: cardiology. Dia/obes: 
diabetes-obesity. Hematol: hematology. Immunol: immunology. Oncol: oncology. Ophthal: ophthalmology. Pain ther: pain therapy. Pneumol: pneumology. Psyc: 
psychiatry. Repr med: reproductive medicine. Reumat: rheumatology. Urology/nephr: urology-nephrology.
Table 2. Break-down of papers per type of disease.
Diseases Science 1990
Nature 
1990
Science 
2000
Nature 
2000
ALS/motor neuron disease — 1 1 —
Alzheimer’s disease 1 1 2 5 (–2 mixed)
Huntigton’s disease — — 1 1
Multiple sclerosis 1 1 1 1 (sympt)
Muscle diseases 1 2 — —
Neurodegenerative diseases — — 3 2
Neuroplasticity/regeneration 1 1 — 3
Neuroprotection 4 — 1 —
Parkinson’s disease 3 — 3 1 (+2 mixed)
Prion diseases — — 2 1
Schizophrenia — — 2 —
Pain — — 2 1
Others — 2 2 2
Total 11 8 20 17
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1991, 6: 288–292), the authors write, “lesioning of the 
STN in the parkinsonian primate is a logical extension 
of previous (1980s) work from this unit…the STN takes 
on a pivotal role in the mechanisms central to Parkin-
sonism. This has been conﬁ rmed in studies where…ibo-
tenic acid lesion of the STN relieved limb hypokinesia,” 
that is, referring to the Bergman et al.’s study.
(2) The grafting of embryonic stem cells (Lindvall et al., 
Feb. 2) has not proven effective for Parkinson’s disease 
in randomized trials.
(3) NGF and congeners never made it into the clinic (Mai-
sonpierre et al., Mar. 23).
It is worth remembering how the first papers leading to 
the DOPA treatment of Parkinson and cholinesterase inhibi-
tors for Alzheimer were published respectively in a German 
journal (Arch. Psychiatr. Nervenkr. Z. Gesamte Neurol. Psychiatr., 
1962, 203: 560–574) and in the Lancet (1977, Mar. 26: 668–671), 
not in Nature or Science.
Special consideration applies to multiple sclerosis (MS). 
The most widely accepted hypothesis for the cause of MS—
an autoimmune reaction against myelin-related proteins—
remains just that, “a hypothesis, one of several,” and “MS 
may be primarily a degenerative disorder rather than…pri-
marily an autoimmune disease” [7, 8]. So it should come as 
no surprise that a 16 year assessment of the efﬁ cacy of inter-
feron B1b, an immune-modulating drug, found no differenc-
es in outcome with placebo-treated patients using standard 
disability and magnetic resonance imaging (MRI) mea-
sures [9]. There is no reason to believe that newer immune-
modulating drugs will fare any better when very long-term, 
independent follow-up data becomes available. All papers 
dealing with MS in both Nature and Science have proved o 
be therapeutically irrelevant and all turned on the immune 
hypothesis. Cannabinoids (Baker et al., Nature, 2000, Mar. 2) 
certainly do not represent a major advancement in the symp-
tomatic treatment of MS; for example, the evidence finds 
cannabis of little beneﬁ t for central pain and with intrinsic 
toxicity [2].
We should stress that a similar analysis was carried out for 
all other medical disciplines, and the results hold up across 
the board, including infectivology, arguably the most suc-
cessful of all medical specialties (unpublished results).
2 State of affairs
Nature and Science are not medical journals, but carry articles 
dealing with neurological research. We have now shown that 
all these neurologically oriented papers are therapeutically 
irrelevant, over a period of 20 years, in that they either lead 
nowhere or, when they do lead to practical results, similar 
research published elsewhere has contributed equally or to a 
greater extent. Paradoxically, this result is conﬁ rmed by the 
many “notes added in proof” that are scattered among the 
hundreds of reviewed papers, which cite simultaneous re-
search published elsewhere that bears out their conclusions. 
Of course, it is possible that once in a while a true “gem” gets 
published, but in the face of our results the odds against it are 
high. It truly appears that scientific “journals often contain 
poor science…publishing studies that are scientiﬁ cally weak 
(in that their conclusions are not supported by their methods 
and data) and irrelevant to practitioners (and so patients)” 
[10]. Ioannidis went so far as to suggest that most published 
research ﬁ ndings are false [11], adding that 
…few advances in biomedical science materialize into human 
applications that affect health…the excuse that not enough time 
has passed is not really satisfactory…intellectual fascination in 
neuroscience for many decades has led to few new practical ap-
plications. It is unclear whether newly announced efforts in this 
extremely interesting discipline will fare any better…most Nobel 
prizes in medicine have been given recently for discoveries that 
offer brilliant mechanicistic insights, but have not yet moved (and 
may never substantially move) the dial of life expectancy. [12]
In the opening citation, Brunton adds, “We have the capac-
ity and ingenuity to correct these shortcomings.” How?
It may be argued that, among many possible reasons for 
such humbling and disconcerting failure, including biologic 
processes simply being too complex for our current capabili-
ties, two reasons stand out: “…peer review…(being) slow, 
expensive, ineffective, something of a lottery, prone to bias 
and abuse, and hopeless at spotting errors and fraud” [10] 
and animal models of human disease being irrelevant (e.g., 
Ref. [13]). As long as these two “pillars of failure” are not re-
dressed dramatically, we can conjure no reason for hope. In 
the meantime, medically relevant research published in both 
Nature and Science should not make it into the media and 
delude patients (“Journals have an unhealthy relationship 
with the mass media…(they) might indeed be degenerating 
into a branch of show business” [10]). The “fall of modern 
medicine” [14] is both a reality and an embarrassment. Thus, 
we can certainly aver that “The future of safe and effective 
patient care” [1] does not lie in basic research and that, in eco-
nomically dire times, the billions poured on such endeavors 
can be safely rerouted to more innovative, human based ex-
perimentation.
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